Company Overview
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -93.57% |
| 6 Months: | -86.67% |
| 3 Months: | -61.93% |
| 1 Month: | -63.58% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)22.18 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 97.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 22 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BCAB BioAtla, Inc. PHARMA | 1.26 | -0.05 | $2.10M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 300.00K | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - |
| Operating Income | -1.11M | -4.52M | -8.02M | -18.80M | -30.46M | -23.70M | -24.35M | -29.05M | -26.18M | -28.93M | -37.20M | -35.02M | -24.46M | -21.97M | -11.27M | -17.61M | -18.65M | -13.79M | -9.31M |
| Net Income | -1.60M | -6.22M | -11.63M | -18.70M | -30.38M | -22.93M | -24.25M | -28.91M | -25.78M | -27.46M | -35.75M | -33.33M | -23.23M | -21.07M | -10.59M | -15.33M | -18.71M | -15.78M | -6.34M |
| Diluted EPS | - | - | - | - | -0.90 | -0.68 | -0.65 | -0.77 | -0.69 | -0.58 | -0.75 | -0.70 | -0.48 | -0.44 | -0.22 | -13.16 | -0.32 | -0.27 | -4.22 |
| R&D Expense | 1.66M | 2.92M | 4.86M | 10.42M | 14.85M | 16.55M | 16.92M | 20.71M | 19.84M | 21.70M | 30.96M | 28.40M | 18.85M | 16.20M | 16.39M | 12.36M | 13.68M | 9.54M | 4.58M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | 300.00K | - | - | - | - |
| Operating Income | -28.27M | -30.10M | -96.44M | -108.14M | -129.69M | -73.94M | -59.30M |
| Net Income | -29.86M | -35.85M | -95.40M | -106.48M | -123.46M | -69.78M | -59.61M |
| Diluted EPS | - | - | -2.76 | -2.74 | -2.58 | -1.44 | -1.01 |
| R&D Expense | 25.92M | 19.93M | 58.27M | 79.35M | 103.73M | 63.09M | 43.57M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 244.94M | - | 225.74M | 119.66M | 52.42M | 13.83M |
| Current Assets | - | - | - | - | 220.43M | 116.41M | 51.23M | 8.01M |
| Cash & Equivalents | 10.86M | 3.70M | 238.60M | - | 215.51M | 111.47M | 49.05M | 7.12M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 34.96M | - | 45.40M | 48.99M | 38.16M | 50.02M |
| Current Liabilities | - | - | 32.26M | - | 23.13M | 28.34M | 14.54M | 21.92M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 3.98M | 2.46M | 836.00K | 6.20M |
| Total Equity | -28.45M | -56.01M | 209.97M | - | 180.34M | 70.67M | 14.27M | -36.19M |
| Shares Outstanding | - | - | - | - | 2.14M | 961.55K | 1.16M | 1.27M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.64M | -36.33M | -62.21M | -90.42M | -104.02M | -71.94M | -48.20M |
| Investing Cash Flow | -1.51M | -590.00K | -924.00K | -265.00K | -98.00K | 0 | - |
| Financing Cash Flow | 4.00M | 271.82M | 69.51M | 61.21M | 77.00K | 9.51M | 6.28M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -32,146.7% | - | - | - | - |
| Net Margin % | - | - | -31,800.7% | - | - | - | - |
| ROE % | 53.3% | -17.1% | - | -59.0% | -174.7% | -489.1% | 164.7% |
| ROCE % | - | -14.2% | - | -53.4% | -142.0% | -195.2% | 732.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Acorn Capital Advisors, LLC | 6.49% | 108.13K | $184.90K |
| 2 | Millennium Management Llc | 4.24% | 70.62K | $120.75K |
| 3 | Lido Advisors, LLC | 1.00% | 16.66K | $28.48K |
| 4 | Stonepine Capital Management, LLC | 0.99% | 16.43K | $28.10K |
| 5 | Acadian Asset Management. LLC | 0.86% | 14.29K | $24.44K |
| 6 | HRT Financial LP | 0.80% | 13.28K | $22.70K |
| 7 | Geode Capital Management, LLC | 0.77% | 12.82K | $21.92K |
| 8 | Deutsche Bank AG | 0.63% | 10.56K | $18.05K |
| 9 | Blackrock Inc. | 0.58% | 9.62K | $16.44K |
| 10 | Vanguard Capital Management LLC | 0.55% | 9.16K | $15.67K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BCAB
BioAtla (BCAB) CFO’s stock move is a tax withholding, not a sale - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPZS1iM1pHWEZpOUlvX3RGZGEtYklZd3hmczNzNThvV1R5MjM0QUg4bXpQNFNzYVB6TmlBT2xUZmdLM1VqbjdiRlFlaFhQcXhNbzk3blhObnRRTUpmQThPeDFRTnhCeGxTV0hpaTdBNExacGtIb1NQY2E2QnpqMzJGRkNKQklRNjk0b01HZX…
BioAtla (BCAB) CMO has RSU shares withheld for taxes - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOVGRYT25ZLWpNY0V5dmlYMXFVLUw0dHhSeDZtYmRBSHo1Q1RoQ0dySlpYNGJUXzJDMVpyQk04akxzczJkUjlZTmw1SjVvb1JrU2FFNk1YcGJ5a3hnSzNMVzBIX0FiMHc5X2xfOEN6X2w2ZDNVS0JsUFJReUFWY3pxTk9KdGlqRWhTT1gtdW…
ETFs Investing in BioAtla, Inc. Stocks - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBkYTFGSTBodkEtQVZGQkd5bmRRbnU3SE1EOHBpSlNnMzRFd292cG9JZm1CODQwYk9UQU9YTjQ1OGx3X2ZXVm5ZUUUtbjhTZDRSc0ZleFl4dmg3dXRLdnFF?oc=5" target="_blank">ETFs Investing in BioAtla, Inc. Stocks<…
BioAtla Announces Share Consolidation - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPUUhNWmVwOERTbTFJRWo0dnVQUno1MGxseGdLRkJidVFDYlVkajZxRmpiM0I5WjFnYlpiMV9iVkVMcHNIMmdPdjYzeFE5Z1JJdnJoZ0dQbUQyQ1h0RWFYbl9maW00OF9raEdWTzhGNjFIZDlwZGVqWjQ0MVBFaTktbFFmYjEyTmlKd0xTNH…
8/28/2026 Market Update - Winners: FNGR, CHAI, CYAB - Losers: BTAI, BCAB, PPCB - S&P 500: -0.2% - Trefis
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPdHlGZXlaYk1kcVRIdGo2dS1GREN0UkpJZ1hXTzVncUFzdi1hb3ZtTXcxMEgzem9TMk5pU09QU0pPV0pTSFFvanBkODR5NWZ0SHp1aGtBWVZINHp3SXFiLVNNLU5ha2xfNWpDNmxab0VJNEoxMWtrU1RySDNBTjNsYmo4a0VKX0pDZHk0al…
BioAtla, Inc.(NasdaqCM: BCAB) dropped from S&P TMI Index - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQUENzemx4RGIycWxxamZsOE1jdko5TzFpOGtCeU8tcnR6d3NIb2JlTW9mUmtqeXVTQVV6R25pUDFsVHdIODl4dXhhVDIxNzJUVGNJZXcxRGxqNGhBMjlFS0dJVTRycTh4WkFFU01MRkJIOTNFLUVNQkxLRHpHX253dDR2WkRGeFZUOE53cD…
BCAB — Frequently Asked Questions
What is the current share price of BioAtla, Inc. (BCAB)?
As of 2026-09-19 21:16 PDT, BioAtla, Inc. (BCAB) trades at $1.26 on NasdaqCM. Its 52-week range is $1.08 to $61.00.
What is the market capitalisation of BCAB?
BioAtla, Inc. (BCAB) has a market capitalisation of $2.10M on NasdaqCM.
What is the P/E ratio of BCAB?
BCAB trades at a trailing price-to-earnings (P/E) ratio of -0.05. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.06.
Is BCAB a good stock to buy?
This page provides a data-driven analysis of BioAtla, Inc. (BCAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.